Search Results

Penumbra’s CAVT With Anticoagulation Studied in STORM-PE

October 27, 2025—Penumbra, Inc. announced that the results of the STORM-PE randomized controlled trial showed that mechanical thrombectomy using the company’s computer assisted vacuum thrombectomy (CAVT) system with anticoagulation achieved superior reduction in right heart strain compared to anticoagulation therapy alone in patients with acute intermediate–high-risk pulmonary embolism (PE).

Penumbra’s STORM-PE Pivotal Trial of Lightning Flash CAVT Completes Enrollment

June 16, 2025—Penumbra, Inc. announced the completion of enrollment in the pivotal STORM-PE prospective, multicenter, randomized controlled trial.

Penumbra’s CAVT Evaluated in 90-Day STORM-PE Data

April 13, 2026—Penumbra, Inc. announced 90-day results of the STORM-PE randomized controlled trial (RCT) that is evaluating computer-assisted vacuum thrombectomy (CAVT) using Penumbra’s Lightning Flash device plus anticoagulation versus anticoagulation alone for the treatment of patients with acute intermediate-high risk pulmonary embolism (PE).

Thrombolex Bashir Catheter Cleared by FDA to Treat Acute Pulmonary Embolism

April 20, 2023—Thrombolex, Inc. announced FDA 510(k) clearance for use of the company’s Bashir and Bashir S-B endovascular catheters for the pharmacomechanical catheter-directed thrombolysis (PMCDT) treatment of acute pulmonary embolism (PE).

Penumbra Enrolls First Patient in STORM-PE Trial for Lightning Flash Thrombectomy in Acute PE

November 28, 2023—Penumbra, Inc. announced that the first patient was enrolled in the prospective, multicenter STORM-PE randomized controlled trial (RCT), which is evaluating anticoagulation alone versus anticoagulation plus Penumbra’s Lightning Flash for the treatment of pulmonary embolism (PE).

Thrombolex’s Bashir Catheter for Acute PE Evaluated in Subanalysis of RESCUE Trial

March 6, 2023—Thrombolex, Inc. announced findings from a subanalysis of the RESCUE trial of pharmacomechanical catheter-directed thrombolysis (PMCDT) therapy using the company’s Bashir endovascular catheter in patients with acute pulmonary embolism (PE).